These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34741082)

  • 61. Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome.
    Liu Z; Liang S; Wei X; Du X; Zhang J
    BMC Gastroenterol; 2022 Dec; 22(1):525. PubMed ID: 36526956
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS).
    Lévy V; Azoulay D; Rio B; Vincent F; Rabbat A; Hunault M; Bazarbachi A; Delmer A; Zittoun R
    Bone Marrow Transplant; 1996 Aug; 18(2):443-45. PubMed ID: 8864460
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications.
    Chen Y; Ye P; Li Y; Ma S; Zhao J; Zeng Q
    Eur Radiol; 2015 Dec; 25(12):3431-7. PubMed ID: 25903717
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease.
    Smith FO; Johnson MS; Scherer LR; Faught P; Breitfeld PP; Albright E; Hillier SC; Gowan D; Smith PD; Robertson KA; Emanuel D
    Bone Marrow Transplant; 1996 Sep; 18(3):643-6. PubMed ID: 8879632
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation.
    Ronald J; Wang Q; Choi SS; Suhocki PV; Hall MD; Smith TP; Kim CY
    Diagn Interv Imaging; 2018 Mar; 99(3):163-168. PubMed ID: 29154015
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic factors with the use of the transjugular intrahepatic portosystemic shunt for bleeding varices.
    Tyburski JG; Noorily MJ; Wilson RF
    Arch Surg; 1997 Jun; 132(6):626-30; discussion 630-2. PubMed ID: 9197855
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
    Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
    United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transjugular Intrahepatic Portosystemic Shunt Through the Strut of a Previously Placed Stent: Technical Feasibility and Long-Term Follow-Up Results.
    Ahmed M; Keshava SN; Moses V; Chiramel GK; Mammen S; Eapen CE; Zachariah UG
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1794-1798. PubMed ID: 30014251
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt.
    Lin X; Gao F; Wu X; Cai W; Chen X; Huang Z
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):862-871. PubMed ID: 32541240
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transjugular Intrahepatic Portosystemic Shunt for Extrahepatic Portal Venous Obstruction in Children.
    Lv Y; He C; Guo W; Yin Z; Wang J; Zhang B; Meng X; Cai J; Luo B; Wu F; Niu J; Fan D; Han G
    J Pediatr Gastroenterol Nutr; 2016 Feb; 62(2):233-41. PubMed ID: 26381818
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.
    Narahara Y; Kanazawa H; Fukuda T; Matsushita Y; Harimoto H; Kidokoro H; Katakura T; Atsukawa M; Taki Y; Kimura Y; Nakatsuka K; Sakamoto C
    J Gastroenterol; 2011 Jan; 46(1):78-85. PubMed ID: 20632194
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Hepatic venousaplasty and transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome with occlusion of the hepatic veins].
    Wu XJ; Cao JM; Han JM; Li JS
    Zhonghua Wai Ke Za Zhi; 2013 Feb; 51(2):131-4. PubMed ID: 23711005
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision.
    Rowley MW; Choi M; Chen S; Hirsch K; Seetharam AB
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1765-1772. PubMed ID: 29872892
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation.
    Fried MW; Connaghan DG; Sharma S; Martin LG; Devine S; Holland K; Zuckerman A; Kaufman S; Wingard J; Boyer TD
    Hepatology; 1996 Sep; 24(3):588-91. PubMed ID: 8781329
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats.
    Chen X; Ma J; He Y; Xue J; Song Z; Xu Q; Lin G
    Phytomedicine; 2021 Aug; 89():153595. PubMed ID: 34153877
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advanced hemodynamic monitoring before and after transjugular intrahepatic portosystemic shunt: implications for selection of patients--a prospective study.
    Saugel B; Phillip V; Gaa J; Berger H; Lersch C; Schultheiss C; Thies P; Schneider H; Höllthaler J; Herrmann A; Schmid RM; Huber W
    Radiology; 2012 Jan; 262(1):343-52. PubMed ID: 22025732
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transjugular intrahepatic portosystemic shunt treatment of variceal bleeding in an unselected patient population.
    Rosenqvist K; Sheikhi R; Nyman R; Rorsman F; Sangfelt P; Ebeling Barbier C
    Scand J Gastroenterol; 2018 Jan; 53(1):70-75. PubMed ID: 28990812
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
    Wang Q; Lv Y; Bai M; Wang Z; Liu H; He C; Niu J; Guo W; Luo B; Yin Z; Bai W; Chen H; Wang E; Xia D; Li X; Yuan J; Han N; Cai H; Li T; Xie H; Xia J; Wang J; Zhang H; Wu K; Fan D; Han G
    J Hepatol; 2017 Sep; 67(3):508-516. PubMed ID: 28506905
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.